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RESEARCH ARTICLE Open Access
Circulating miRNAs miR-34a and miR-150 associated
with colorectal cancer progression
Sinéad T Aherne1*, Stephen F Madden1, David J Hughes2, Barbara Pardini3, Alessio Naccarati3,5, Miroslav Levy4,
Pavel Vodicka5, Paul Neary6, Paul Dowling1,7 and Martin Clynes1
Abstract
Background: Screening for the early detection of colorectal cancer is important to improve patient survival. The aim
of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency
at delineating patients with polyps and benign adenomas from normal and cancer patient groups.
Methods: The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal,
polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further
examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset
of 40 CRC samples and paired normal tissues.
Results: High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from
those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from
those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent
public dataset of forty CRC samples and paired normal tissues was confirmed.
Conclusion: We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of
the colon from each other, and patients with advanced cancer from benign disease groups.
Keywords: Colorectal cancer, Circulating miRNAs, miR-34a, miR-150, miR-923
Background
Colorectal cancer (CRC) poses a significant threat to the
health of global populations; it is the second most com-
monly diagnosed cancer in females and the third in
males [1]. CRC develops in a progressive fashion during
which normal colon epithelial cells transform to form
benign growths such as polyps. These polyps may then
progress to benign adenomas, and ultimately to invasive
cancer lesions. The progression of the cancer has also
been associated with sequential genetic changes in genes
such as K-RAS, APC, DCC, and P53 [2]. However CRC
is a heterogeneous disease with various patient-related
confounding factors such as the anatomic location of the
tumour, race/ethnicity of the patient, and genetic and
dietary interactions influencing the development of the
disease [3].
Screening at risk populations for CRC has significantly
improved the outcome for patients, for instance diagno-
sis while the disease remains localised to the colon dra-
matically improves patient survival, and removal of early
lesions such as adenomatous polyps may prevent disease
formation [4]. There are currently several potential
screening tests available to detect CRC including the fae-
cal occult blood test (FOBT), flexible sigmoidoscopy
(FS), optical colonoscopy (OC) and computed tomog-
raphy colonography (CTC). FOBT is a simple, cheap
and safe test that relies on the assumption that large ad-
enomas and cancerous lesions may bleed, and that these
blood products are detectable in the faecal matter of pa-
tients. Although cheap and non-invasive, this test is vul-
nerable to false positive and negative results due to
incorrect sample storage, or confounding medical com-
plaints such as haemorrhoids. The other examinations
involve more costly and invasive procedures which al-
though allow direct access to colorectal lesions also* Correspondence: sinead.aherne@dcu.ie1Molecular Therapeutics for Cancer Ireland, National Institute for Cellular
Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
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suffer from low patient acceptance and procedural risks
such as perforation of the colon [4].
The focus of the scientific community has thus shifted
to exploring the identification of non-invasive bio-
markers of disease from bio-fluids such as saliva, urine,
and blood. MicroRNAs (miRNAs) are nucleic acid
markers that have been recently investigated in this con-
text. MiRNAs are short (20-22nt) non-coding RNAs that
negatively regulate gene expression through either
mRNA degradation or translational repression [5].
MiRNA expression has been shown to be altered in can-
cerous tissue compared to normal tissue and different
miRNAs have been attributed oncogenic and tumour
suppressor qualities [6]. In 2008, Chen et al. detected
miRNAs in the serum and plasma blood components of
humans and other animals. This primary study illus-
trated that miRNAs remain stable in serum after being
subject to severe conditions such as extremely low or
high pH, 10 freeze-thaw cycles, extended storage, boil-
ing, and RNase digestion [7]. In addition to their pres-
ence in serum and plasma, miRNAs have also been
detected in other body fluids such as urine, saliva, and
amniotic fluid making them ideal potential candidates as
non-invasive biomarkers of disease [8].
Expression levels of circulating miRNAs have shown
some potential at distinguishing cancer patients and
healthy controls for prostate [9], ovarian [10], lung
[11,12], and breast cancers [13]. Several studies have also
investigated circulating miRNA levels for the detection
of CRC. Initial approaches analysed small numbers of
circulating miRNAs in CRC patient samples compared to
normal controls [14]. Other groups performed miRNA
profiling on pooled plasma samples and validated candi-
date biomarkers on additional individual samples [15],
and others performed profiling on a small number of CRC
tissue/serum/plasma samples before validation in a larger
sample set [16]. These studies have produced conflicting
results [17] and so recently, groups have begun to perform
profiling on larger sample sets and included plasma from
patients with adenomas in addition to CRC to improve
the specificity of disease detection [18].
In 2008, a guideline was released from the American
Cancer Society which highlighted the importance for pa-
tients to have access to screening tests that will facilitate
cancer prevention through the early detection of cancer,
and the detection and removal of polyps [4]. A clear deficit
in the search for circulating biomarkers for the early de-
tection of CRC to date is the lack of adenomatous polyp
samples and the lack of separation of advanced and early
stage cancers represented in studies [14-16,18-20]. The
aim of this study was therefore to investigate the potential
of circulating cell-free miRNAs not only as biomarkers of
CRC, but also their efficiency at delineating patients pre-
senting with polyps and benign adenomas from normal
and cancer groups. To facilitate this we performed
miRNA profiling for 667 miRNAs on a discovery set of 48
plasma samples comprising 8 normal, 8 polyp, 16 aden-
oma samples, 8 early stage cancer samples (stage I/II), and
8 advanced cancer samples (stage III/IV). Three candidate
miRNAs; miR-34a, miR-150, and miR-923 were then fur-
ther examined in a validation cohort of 97 independent
plasma samples comprising 20 normal, 20 polyp, 20 aden-
oma samples, 23 early stage cancer samples, and 14 ad-
vanced cancer samples. In addition, we confirmed the
altered expression of two of the miRNAs in an independ-
ent dataset of 40 CRC samples and their paired normal
tissues. We found circulating levels of miR-34a and miR-
150 to be capable of distinguishing patients groups with
benign and malignant diseases of the colon from each
other, and sets of miRNAs that distinguish patients with
advanced cancer from benign disease groups. Specifically,
we found high levels of circulating miR-34a and low miR-
150 levels to distinguish patients with polyps from those
with advanced cancer, and low circulating miR-150 levels
to separate patients with adenomas from those with ad-
vanced cancer.
Methods
Patients selection and sample collection
Cases with positive colonoscopy results for malignancy,
confirmed by histology as colon or rectal carcinomas,
were recruited between December 2007 and December
2010 at the Department of Surgery, Adelaide and Meath
Hospital and at the Thomayer Hospital in Prague, Czech
Republic. Control subjects or subjects diagnosed with
polyps or adenomatous polyps were selected during the
same period from individuals undergoing colonoscopy
for various gastrointestinal complaints (macroscopic
bleeding, positive faecal occult blood test or abdominal
pain of unknown origin). The participating subjects gave
written informed consent in accordance with the Declar-
ation of Helsinki at the precipitating site that was ap-
proved by Tallaght Hospital/St. James’s Hospital Joint
Research Ethics Committee, The Adelaide and Meath
Hospital, Dublin, Incorporating The National Children’s
Hospital, Tallaght, Dublin 24, Ireland and the Ethical
Committee of the Institute of Experimental Medicine,
Prague, Czech Republic. See Table 1 for clinical informa-
tion on samples used.
Two separate patient cohorts were identified, a discov-
ery set (n = 48) comprising 8 normal, 8 polyp, 16 aden-
oma samples, 8 early stage cancer samples (stage I/II),
and 8 advanced cancer samples (stage III/IV), and a val-
idation set (n = 97) comprising 20 normal, 20 polyp, 20
adenoma samples, 23 early stage cancer samples, and 14
advanced cancer samples. In addition, an independent
public dataset [21] of quantitative real-time PCR (qRT-
PCR) raw data was downloaded from the NCBI GEO
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archive (accession no: GSE28364) which contains infor-
mation on 40 CRC samples and their paired normal
tissues.
Plasma samples were collected according to standard
phlebotomy procedures. 10 ml of blood sample was col-
lected into EDTA plasma tubes and immediately placed
in ice. The tubes were centrifuged at 1000 x g for 10 mi-
nutes at 4°C. Plasma was denuded by pipette from the
cellular material, aliquoted into cryovial tubes, labelled
and stored at -80°C until the time of analysis. The time
from sample procurement to storage at -80°C was less
than 3 hours. Each plasma sample underwent no more
than 3 freeze/thaw cycles prior to analysis.
RNA extraction
Total RNA was isolated from 60 μl of each plasma sample
using the miRNeasy mini kit (Cat no 217004, Qiagen).
The Qiagen supplementary protocol (Purification of total
RNA, including small RNAs, from serum or plasma) was
utilised with the following modifications: thawed plasma
samples were centrifuged at 1000 x g for 5 minutes at 4°C
to remove excess debris from samples, RNA was extracted
from the upper 50 μl of each sample. To elute the RNA,
50 μl of nuclease-free water was added to each spin column
and incubated for 1 minute at room temperature before
centrifuging into non-stick RNase-free microfuge tubes
(Cat no AM12350, Ambion) to elute the RNA.
MiRNA profiling of plasma with TaqMan® low-density
arrays
TaqMan® Array Human MicroRNA A and B Cards v2.0
(Cat no 4400238, Applied Biosystems) were employed to
examine the expression of 667 miRNAs in 48 plasma
samples in the discovery cohort. Reverse transcription
and quantitative PCR (qPCR) were performed on equal
volumes of RNA from each sample according to the manu-
facturer’s instructions using TaqMan® MicroRNA Reverse
Transcription Kit (Cat no 4366596, Applied Biosystems)
and Megaplex RT Primers to convert the miRNAs to
cDNA, TaqMan® PreAmp Master Mix (Cat no 4391128,
Applied Biosystems) and Megaplex PreAmp Primers for a
preamplification step before real-time analysis. qPCR was
performed using TaqMan® Universal Master Mix II, no
UNG (Cat no 4440048, Applied Biosystems) on the
7900HT Fast Real-Time PCR system (Applied Biosystems).
The Sequence Detector System software version 2.2.2 was
utilised to generate study files using a fixed threshold value
of 0.1 for statistical analysis (accession no: GSE67075).
Validation of miRNA expression using qRT-PCR
Individual TaqMan® miRNA assays were used for
miRNA quantification in the 97 plasma samples in the
validation cohort. To improve reverse transcription effi-
ciency a miRNA multiplex RT primer pool was made
from the singleplex RT primers of the four miRNAs to
be analysed; miR-34a, miR-150, miR-923, and miR-let7e
(this miRNA was used as the endogenous control as it
showed very little variation in the discovery cohort, ΔCt
SD = 0.865). 100 μl of each 20X RT primer were added to
an RNase-free microfuge tube. The tube was dried in a
speed vacuum (MAXI dry plus, Medical Supply Company,
Ireland) at 50°C for 1 hour. The primers were re-suspended
in 100 μl of nuclease-free water and 300 μl of 0.1X TE buf-
fer was added to yield a 5X multiplex RT primer pool. The
TaqMan® MicroRNA Reverse Transcription Kit (Cat no
4366596, Applied Biosystems) was used to perform reverse
transcription reactions. Each reaction contained 1.8 μl of RT
buffer (10X), 0.18 μl of dNTPs (25 mM), 3.6 μl of miRNA
multiplex RT primer pool (5X), 1.2 μl of Multiscribe RT en-
zyme (50 U/μl), 5.22 μl of nuclease-free water and 6 μl of ex-
tracted total RNA. The reactions were incubated at 16°C for
30 minutes, 42°C for 30 minutes and 85°C for 5 minutes
(G-STORM, GS1, Somerton Biotechnology Centre, UK).
Real-time PCR analysis was performed on 96 well
plates (Cat no 4346906, Applied Biosystems). Technical
triplicate PCRs were performed for each sample, and no
template controls and a pooled sample containing cDNA
from all 97 samples were included on each plate to en-
sure inter-plate reproducibility. Each reaction contained
1 μl of TaqMan miRNA assay (20X), 10 μl of TaqMan®
Universal Master Mix II, no UNG (Cat no 4440048,
Applied Biosystems), 7.67 μl of nuclease-free water, and
1.33 μl of cDNA. The reactions were incubated at 95°C
for 10 minutes, and 40 cycles of 95°C for 15 seconds and
60°C for 15 seconds on the 7900HT Fast Real-Time PCR
system (Applied Biosystems). The Sequence Detector
System software version 2.2.2 was utilised to generate
Table 1 Clinical information on the discovery and
validation plasma sample cohorts
Discovery Cohort
n (M/F) Age
Normal 8 (4/4) 67 ± 11
Polyps 8 (4/4) 65 ± 7
Adenoma 16 (8/8) 56 ± 6
Early Stage Cancer (Stage I/II) 8 (4/4) 65 ± 10
Advanced Cancer (Stage III/IV) 8 (4/4) 68 ± 8
Validation Cohort
n (M/F) Age
Normal 20 (12/8) 63 ± 8
Polyps 20 (11/9) 57 ± 7
Adenoma 20 (12/8) 62 ± 10
Early Stage Cancer (Stage I/II) 23 (10/13) 63 ± 12
Advanced Cancer (Stage III/IV) 14 (9/5) 67 ± 8
M denotes male; F denotes female.
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study files using a fixed threshold value of 0.1 for statis-
tical analysis.
Statistical analysis
In the discovery cohort (n = 48), each miRNA was nor-
malised by the ΔΔCt method using the average within
sample Ct value [22]. This technique involves the use of
the mean expression value of all expressed microRNAs
in a given sample as a normalisation factor for micro-
RNA real-time quantitative PCR data. Thus the average
within sample Ct value for each card is calculated by
averaging all miRNA Ct values for each individual sam-
ple. This was performed using the Bioconductor package
HTqPCR (www.bioconductor.org). The non-parametric
Kruskal-Wallis test was used to determine between
group variations by rank as the data was not normally
distributed. A Wilcoxon rank sum test was subsequently
used to perform pair-wise comparisons between the 5
groups for the significant miRNAs identified by the
Kruskal-Wallis test.
As an alternative to spiking un-related miRNA con-
structs into our samples we utilised the miRNA profiling
data of the discovery cohort of samples to choose an ap-
propriate endogenous control for use in the validation
cohort. This involved analysing the expression of all 667
miRNAs across all 48 samples in the discovery cohort
allowing us to choose one of the least variant miRNAs.
As MammU6 showed highly variant expression in the
discovery cohort, miR-let7e was chosen for use as an en-
dogenous control for the validation set as it was one of
the least variant miRNAs in the discovery phase experi-
ment (ΔCt standard deviation of 0.86). When the let7e
Cts were examined across all samples in the validation
cohort this miRNA proved an appropriate endogenous
control with a Ct standard deviation of 1.64. Statistically
significant differences were determined using the non-
parametric Wilcoxon rank sum test. The p-values for
the validation set were adjusted using the Benjamini and
Hochberg method [23] to account for multiple testing.
For consistency, the independent public dataset from
Reid et al. [21] (accession no: GSE28364) was normal-
ised using the same approach used to analyse the discov-
ery cohort qRT-PCR data. This independent study used
TaqMan® Array Human MicroRNA Cards v2.0 to ana-
lyse miRNA expression in 40 CRC tumour samples and
their paired normal tissues. In order to mimic this struc-
ture in our validation plasma sample cohort, we grouped
samples into ‘non-malignant’ and ‘malignant’ groups. As
there were only two groups (normal versus cancer) in
this analysis, the Wilcoxon rank sum test was used to
determine significantly differentially regulated miRNAs.
For this analysis of the validation cohort, miR-34a, miR-
150 and miR-923 were first normalised against the en-
dogenous control (miR-let7e) and the Wilcoxon rank
sum test was used to determine significance between the
groups.
Logistic regression (LR) and receiver operator charac-
teristic (ROC) curve analysis were performed on miR-
34a, miR-150 and miR-923 in the validation cohort. The
markers were combined using LR and the ROC curves
were used for interpretation of the models generated.
The area under the curve (AUC) from the ROC curve
for a given model was used to determine the probability
of a correct prediction. The LR model for single miR-
NAs or combinations of miRNAs which gave the highest
AUC was considered the most discriminating model and
therefore the best marker at distinguishing between the
groups of interest. All calculations were carried out in
the R statistical environment (http://cran.r-project.org/)
using the HTqPCR and stats packages.
Results
Differential expression of miRNAs in the discovery cohort
This study examined the expression of 667 miRNAs in
plasma samples of a discovery cohort of 48 patients with
benign and malignant disease of the colon compared to
age and sex matched disease-free controls (Table 1).
Statistical analysis revealed 73 miRNAs that have signifi-
cantly different levels (p-value <0.05) in at least one of the
disease groups (polyp n = 8, adenoma n = 16, early stage
cancer (stage I/II) n = 8, and advanced cancer (stage III/IV)
n = 8) compared to the healthy controls n = 8 (Table 2).
Forty miRNAs were significantly different in advanced can-
cer, 22 in early stage cancer, 7 in adenoma, and 22 in the
polyp group compared to normal controls. Ten miRNAs
were significantly altered in both the early stage and ad-
vanced cancer groups compared to the normal controls;
miR-923, miR-801, miR-144*, miR-135a*, miR-500, miR-
497, miR-150, miR-30c and RNU48 showed lower levels
while miR-532-3p was more abundant in the cancer
groups compared to the controls. MiR-34a was signifi-
cantly higher in early stage cancer compared to healthy
controls.
miRNAs were prioritised for subsequent confirmation
in the validation sample set if they showed consistently
altered levels between the control group and each of the
disease groups, and if all or most of these changes were
deemed to be statistically significant. MiR-34a was
chosen for validation as it was increased in the plasma of
diseased patients compared to controls. MiR-150 and
miR-923 were chosen for validation as their plasma levels
progressively decreased as the sample/disease groups pro-
gress toward malignancy (Table 2).
Altered levels of miR-34a, miR-150, and miR-923 in the
validation cohort
The three candidate miRNAs; miR-34a, miR-150, and miR-
923 were analysed in a validation cohort of 97 independent
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Table 2 miRNAs with significantly different levels in disease groups compared to normal in the discovery cohort
MiRNAs Normal vs Polyp Normal vs Adenoma Normal vs Early Cancer Normal vs Late Cancer
Log2 FC P Value Log2 FC P Value Log2 FC P Value Log2 FC P Value
hsa-let-7b −0.823 0.007 −0.618 0.038 −0.712 0.083 −0.298 0.328
hsa-let-7c 3.407 0.442 4.27 0.136 4.794 0.105 0.812 0.753
hsa-let-7g −0.749 0.195 −0.231 0.153 −1.177 0.010 −3.933 0.234
hsa-miR-135a 13.518 0.050 0.614 0.968 −5.76 0.171 3.738 0.655
hsa-miR-140-5p 0.672 0.038 0.122 0.834 0.558 0.083 −2.645 0.021
hsa-miR-146b-3p 11.496 0.281 −1.962 0.511 −1.377 0.904 10.34 0.043
hsa-miR-150 −0.523 0.161 −0.706 0.032 −1.491 0.015 −2.771 0.000
hsa-miR-15b −0.538 0.130 −0.362 0.238 −2.019 0.001 −0.746 0.105
hsa-miR-182 7.054 0.178 −2.384 0.864 −3.173 0.685 −11.924 0.032
hsa-miR-183 −0.192 0.599 −1.533 0.667 −3.09 0.792 −15.707 0.010
hsa-miR-190 −0.139 0.874 −9.03 0.043 −16.68 0.018 −7.941 0.075
hsa-miR-191 0.138 0.505 −0.049 0.383 −0.979 0.083 0.509 0.279
hsa-miR-192 3.363 0.721 2.913 0.061 3.349 0.505 −2.113 0.036
hsa-miR-193a-5p 4.76 0.105 2.668 0.417 3.744 0.798 −1.73 0.012
hsa-miR-194 2.184 0.105 2.992 0.452 3.008 0.234 −1.904 0.016
hsa-miR-199a-3p 1.037 1.000 −0.095 0.264 −0.217 0.234 −2.353 0.010
hsa-miR-19a 1.229 0.050 0.318 0.976 1.58 0.028 0.831 0.083
hsa-miR-19b 1.125 0.010 0.302 0.976 1.447 0.065 0.696 0.028
hsa-miR-204 12.069 0.005 6.087 0.096 6.565 0.751 3.338 0.790
hsa-miR-210 2.864 0.003 −3.207 0.927 1.987 0.028 −1.692 0.105
hsa-miR-21 −0.232 0.050 −0.239 0.238 0.561 0.130 −3.683 0.065
hsa-miR-219-1-3p −2.985 0.382 −1.557 0.610 3.221 0.488 8.939 0.142
hsa-miR-23a 3.751 0.574 −1.265 0.667 0.948 0.400 3.146 0.012
hsa-miR-25 0.717 0.721 0.052 0.120 0.853 0.574 −0.621 0.038
hsa-miR-30b 0.04 0.721 −0.117 0.452 −0.964 0.028 −0.88 0.130
hsa-miR-30c −0.017 0.878 −0.231 0.172 −0.845 0.038 −6.451 0.038
hsa-miR-323-3p −0.461 0.328 0.328 0.452 0.243 0.574 −2.93 0.130
hsa-miR-337-5p 6.448 0.359 4.019 0.391 3.964 0.547 12.303 0.007
hsa-miR-34a 18.817 0.003 12.09 0.119 15.428 0.018 11.626 0.055
hsa-miR-365 0.257 0.878 −1.16 0.061 −0.884 0.279 −5.763 0.010
hsa-miR-370 9.181 0.040 4.218 0.283 −2.578 0.790 6.114 0.065
hsa-miR-377 0 NA 4.206 0.221 3.063 0.382 14.295 0.013
hsa-miR-451 0.216 1.000 −0.341 0.120 −0.111 0.721 −1.955 0.007
hsa-miR-486-3p −0.225 0.382 0.062 0.569 0.176 0.574 −5.158 0.010
hsa-miR-486-5p −0.813 0.065 −0.241 0.787 −0.562 0.798 −2.187 0.003
hsa-miR-500 −5.223 0.018 −6.169 0.084 −11.283 0.007 −9.256 0.011
hsa-miR-503 −3.035 0.382 −1.631 0.610 −3.035 0.382 7.943 0.225
hsa-miR-532-3p 2.845 0.195 3.061 0.452 1.402 0.015 2.436 0.050
hsa-miR-532-5p 4.749 0.105 3.772 0.787 4.688 0.130 0.31 0.834
hsa-miR-542-3p 3.213 0.382 0 NA 0 NA 7.988 0.076
hsa-miR-548d-3p −3.186 0.382 −0.077 0.958 2.882 0.700 12.243 0.117
hsa-miR-548d-5p 9.445 0.076 1.349 0.536 2.736 0.382 14.573 0.013
hsa-miR-654-3p 10.564 0.012 4.161 0.153 3.815 0.250 11.441 0.007
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plasma samples comprising 20 normal, 20 polyp, 20 aden-
oma samples, 23 early stage cancer samples, and 14 ad-
vanced cancer samples (see Table 3).
Among the three miRNAs analysed in the validation co-
hort, only miR-34a distinguished the normal and precan-
cerous lesion groups from the disease samples (Figure 1A).
MiR-34a expression was significantly increased in the ad-
enoma (FC 2.09, p-value = 0.028) and early stage cancer
(FC 2.84, p-value = 0.002) groups compared to healthy
controls, and moderately in the advanced cancer group
(FC 1.80, p-value = 0.081). The levels of this miRNA
were also significantly higher in the adenoma (FC 2.71,
p-value = 0.002), early stage cancer (FC 3.69, p-value =
3.90e-5) and advanced cancer (FC 2.34, p-value = 0.006)
groups compared to the polyp samples. Alternatively,
miR-150 distinguished the polyp and adenoma groups
from the advanced cancer ((FC -2.31, p-value = 0.007,
FC -2.55, p-value = 0.001 respectively) (Figure 1B). Fol-
lowing adjustment for multiple testing, miR-923 was not
found to have significantly altered levels in the validation
cohort (Figure 1C).
Validation of altered miR-34a, miR-150, and miR-923
expression in an independent dataset of matched colon
tumour and normal tissues
In an effort to determine whether the levels of circulat-
ing cell free miRNAs that were observed in our study
reflected the biology of the tumour, we investigated their
expression in a publically available qPCR dataset of CRC
tumours and matched normal tissues [21]. All miRNAs
Table 2 miRNAs with significantly different levels in disease groups compared to normal in the discovery cohort
(Continued)
hsa-miR-660 0.544 0.234 0.228 0.106 0.447 0.721 −4.865 0.007
RNU48 −3.549 0.365 1.637 0.878 −12.871 0.064 −7.855 0.075
hsa-let-7a-3p 10.399 0.148 8.684 0.217 −6.667 0.171 10.717 0.118
hsa-miR-135-3p −0.835 0.195 −0.512 0.417 −1.688 0.002 −2.27 0.001
hsa-miR-136-3p 5.14 0.028 −0.617 0.357 −0.031 1.000 2.942 0.016
hsa-miR-138-1-3p −0.353 0.065 −0.038 0.697 −0.033 0.721 −1.37 0.038
hsa-miR-144-5p −1.373 0.065 −1.208 0.011 −3.164 0.001 −2.299 0.028
hsa-miR-151-3p 0.398 0.574 0.343 0.697 0.623 0.574 2.57 0.007
hsa-miR-16-1-3p 2.883 0.873 −7.605 0.117 7.397 0.290 4.03 0.424
hsa-miR-221-5p −6.94 0.171 1.828 0.732 −6.94 0.171 10.556 0.183
hsa-miR-222-5p 3.311 0.566 −3.168 0.479 −2.906 0.590 12.137 0.104
hsa-miR-25-5p 18.99 0.018 5.097 0.334 17.026 0.024 12.007 0.117
hsa-miR-30a-3p 0.171 0.382 −0.048 0.881 0.736 0.003 −3.516 0.279
hsa-miR-30e-3p −0.136 0.959 −0.8 0.038 −1.034 0.038 −1.083 0.574
hsa-miR-30e 0.798 0.003 −0.048 0.881 1.107 0.010 0.466 0.065
hsa-miR-497 5.305 0.004 −0.143 0.302 5.1 0.011 4.304 0.001
hsa-miR-509-3p −0.329 0.083 −0.06 0.653 0.825 0.234 −5.263 0.007
hsa-miR-559 −11.278 0.009 1.504 0.991 1.144 0.804 −7.323 0.007
hsa-miR-605 −3.301 0.164 4.458 0.233 −0.111 0.974 12.867 0.006
hsa-miR-609 −1.583 0.349 −0.832 0.613 −0.1 1.000 1.618 0.576
hsa-miR-610 −0.557 0.038 −0.463 0.291 0.493 0.382 −1.327 0.021
hsa-miR-632 −0.766 0.105 −0.495 0.350 0.176 0.721 −2.335 0.010
hsa-miR-645 −1.016 0.019 −0.628 0.135 −0.426 0.224 −5.643 0.001
hsa-miR-668 14.982 0.004 7.463 0.072 −2.096 0.549 11.805 0.017
hsa-miR-7 4.86 0.181 1.229 0.437 5.291 0.048 0.28 0.611
hsa-miR-768-3p 6.126 0.085 −7.483 0.206 −9.603 0.059 −9.625 0.059
hsa-miR-801 1.108 0.270 −0.261 0.787 −3.102 0.000 −6.163 0.008
hsa-miR-923 −1.635 0.000 −1.184 0.001 −2.833 0.000 −6.284 0.007
RNU24 11.491 0.000 9.167 0.000 1.901 0.291 3.178 0.089
RNU48 −3.073 0.074 0.595 0.649 −10.127 0.001 −9.95 0.000
miRNAs highlighted in bold were chosen for validation in the validation cohort of 97 plasma samples.
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found to be significantly differentially expressed in the
independent dataset are listed in Additional file 1. As
this independent dataset only contains information on
cancer and adjacent normal samples, the normal, polyp
and adenoma plasma samples in our validation cohort
were combined into a ‘non-malignant’ group and the
early stage and advanced cancer plasma samples were
combined into a ‘cancer’ group to facilitate comparison
of the miRNA expression changes.
Figure 2 illustrates that the altered levels of all three
circulating miRNAs observed in the plasma samples of
the validation cohort mirrors the expression changes in
the CRC tissues in the independent tissue sample set.
Mir-34a was found to be significantly up-regulated in
both the validation and the independent sample sets,
2.62 fold up-regulated (p-value = <0.001) and 1.71 fold
up-regulated (p-value = 8.50e-6) respectively (Figure 2A).
In further examining the expression of miR-34a in the
combined plasma sample groups in the validation co-
hort, it was observed that it was also able to distinguish
the non-malignant group (normal, polyp & adenoma
groups) from the early stage cancer group (FC = 3.07,
p-value = <0.001), and the normal and polyp groups from
the benign adenoma group (FC = 1.90, p-value = 0.001).
Additionally, miR-150 was significantly down-regulated in
both the cancer plasma (FC = -1.29, p-value = 0.013) and
cancer tissue (FC = -2.55, p-value = 4.104e-08) samples. Al-
though not significantly, miR-923 was also down-regulated
in both the cancer plasma (FC = -1.11, p-value = 0.779) and
cancer tissue (FC = -2.26, p-value = 0.353) samples. See
Table 3 for all FCs and associated p-values for miR-34a,
miR-150, and miR-923 in the validation cohort.
Diagnostic potential of circulating miR-34a, miR-150, and
miR-923 for the detection of disease of the colon
Once the altered expression of miR-34a, miR-150, and
miR-923 was confirmed in our 97 validation plasma
samples, and in the independent tissue samples, LR and
ROC analyses were used to evaluate the potential of
these miRNAs to distinguish between the disease and
control blood plasma samples. First LR was used to
identify the linear model with the best discriminatory
power between sample groups, and the quality of this
model was depicted by the area under the curve (AUC)
of the ROC curve. For individual miRNAs, AUCs ranged
from 0.488 to 0.875 (see Additional file 2). In an effort
to identify the most powerful candidates as diagnostic
markers of disease, we focused on comparing sample
groups that showed significant differential expression of
more than one of the three miRNAs. Thus we have identi-
fied sets of miRNAs that could distinguish advanced can-
cer from benign disease groups (Figure 3). Individually,
plasma levels of miR-34a, miR-150, and miR-923 discrim-
inate polyp samples from advanced cancer samples with
AUC = 0.796 (CI:0.646-0.947), 0.825 (CI:0.681-0.969), and
0.746 (CI:0.412-0.817) respectively. The discriminatory
power of the analysis was improved by combining markers
miR-34a (p-value = 0.016, CI:-2.911- -0.314) and miR-150
(p-value = 0.031, CI:0.392-2.640) which increased the
AUC to 0.904. The Akaike’s Information Criterion (AIC)
was used as a measure of the quality of the model. The
model with the lowest AIC was considered the best fit i.e.
the combination of miRNAs that produced the lowest
AIC. Where the addition of a miRNA did not lower the
AIC it was excluded as the simplest model that best
Table 3 Fold changes and associated p-values for miR-34a, miR-150, and miR-923 in the validation cohort
miR-34a miR-150 miR-923
FC P value FC P value FC P value
Normal vs Polyp −1.3 0.286 1.52 0.218 1.24 0.537
Normal vs Adenoma 2.09 0.028 1.68 0.160 1.19 0.537
Normal vs Early Stage Cancer 2.84 0.002 −1.03 0.800 1.19 0.675
Normal vs Advanced Cancer 1.8 0.081 −1.52 0.282 −1.7 0.537
Polyp vs Adenoma 2.71 0.002 1.11 0.735 −1.04 0.904
Polyp vs Early Stage Cancer 3.69 0.000 −1.57 0.160 −1.05 0.779
Polyp vs Advanced Cancer 2.34 0.006 −2.31 0.007 −2.11 0.113
Adenoma vs Early Stage Cancer 1.36 0.381 −1.73 0.104 −1.01 0.867
Adenoma vs Advanced Cancer −1.16 0.691 −2.55 0.001 −2.03 0.113
Early Stage Cancer vs Advanced Cancer −1.58 0.169 −1.47 0.529 −2.02 0.113
Non-Cancer vs Early Stage Cancer 3.07 0.000 1.42 0.160 1.19 0.675
Non-Cancer vs Cancer 2.62 0.001 1.29 0.013 −1.11 0.779
Normal & Polyp vs Adenoma 1.9 0.002 1.98 0.282 1.08 0.537
Bold text denotes significant comparisons. Non-Cancer comprises normal, polyp & adenoma groups, Cancer comprises both early stage & advanced cancer groups.
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Figure 1 (See legend on next page.)
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describes the data is preferable. MiR-923 expression was
found not to improve the fit of the model and thus was not
included in the combination (Figure 3A). In searching for
an optimal model to distinguish adenoma samples from
advanced cancer samples, it was found that miR-150 alone
(rather than in combination with miR-923) was sufficient
to with an AUC of 0.875 (CI:0.754-0.996) (Figure 3B).
Discussion
Screening for the early detection of CRC is important to
improve patient survival and facilitate cancer prevention
through the detection and removal of polyps. The aim of
this study therefore was to investigate the potential of
circulating cell-free miRNAs not only as biomarkers of
CRC, but also their efficiency at delineating patients pre-
senting with precancerous lesions, i.e. polyps and benign
adenomas from normal and cancer patient groups.
MiRNA profiling was performed in the discovery sample
cohort consisting of five groups; normal, polyps, benign ad-
enomas, early stage cancer, and advanced cancer (Table 2)
and identified three candidate miRNAs (miR-34a, miR-150,
and miR-923) which were then further examined in a valid-
ation cohort of 97 samples divided into the same five
groups as before (Figure 1 and Table 3). In addition, we
confirmed that the altered circulating levels of miR-34a and
miR-150 mirror the expression changes evaluated in the tu-
mours of an independent dataset of 40 CRC samples and
their paired normal tissues (Figure 2).
miR-34a is a p53-regulated miRNA that has been
shown to influence both cellular senescence and apop-
tosis [24,25]. Different studies have demonstrated its up
or down regulation in CRC compared to normal tissue
(as reviewed in [26]). Wu et al. [27] demonstrated the
involvement of this miRNA in CRC invasion and metas-
tasis through targeting FRA1, a FOS transcription factor
that is capable of forming activator protein-1 (AP-1) het-
erodimers. Increased levels of this circulating miRNA
have been detected in patients with chronic hepatitis C
and non-alcoholic fatty liver disease [28] and levels have
been found to be decreased in whole blood samples of pa-
tients with CRC compared to healthy controls [29]. Brunet
and colleagues studied miRNA expression in stage III
CRC tissue samples compared to normal controls and
found miR-34a to be significantly up-regulated [30].
In one of the first studies to investigate the altered ex-
pression of miRNAs in cancer [31] miR-150 was shown
to be up-regulated in colorectal tissue compared to nor-
mal tissue. However several subsequent studies have
shown this miRNA to be down-regulated in CRC tissue
compared to normal tissue [21,32]. Indeed a recent study
on 239 samples from Ma et al. found that miR-150 was
down-regulated in adenoma and CRC tissues compared to
normal tissue, and this down-regulation was associated
with decreased overall survival and a worse response to
adjuvant chemotherapy [33]. Decreased circulating levels
of miR-150 have been identified in patients with acute
myeloid leukaemia [34], and have been associated with
poor prognosis for critically ill patients [35]. Furthermore,
Wang and colleagues found miR-150 expression to be
down-regulated in their 10 pooled CRC plasma samples
compared to 10 pooled control samples, although its al-
tered expression was not validated in their additional indi-
vidual samples [15]. To our knowledge there are no
studies outlining miR-923 expression in CRC or detecting
circulating levels of this miRNA, however it has been
shown to be down-regulated in chronic lymphocytic leu-
kaemia patients [36] and up-regulated in taxol resistant
breast cancer cells [37].
Of the three miRNAs analysed in our validation co-
hort, only miR-34a distinguished the normal group from
the disease groups (Figure 1A). A large amount of inter-
individual variability was noted in the normal samples
assessed for miR-150 and miR-923 expression which may
account for the fact that they do not significantly separate
the normal group from the disease groups (Figure 1B&C).
The reason for this variability may lie in the fact that these
subjects had sufficient medical complaints to present them-
selves for colonoscopy, but although they do not present
polyps, adenomas or cancer of the colon they may have
had other conditions such as irritable bowel disease which
may influence the results. In addition, the high number of
adenoma samples (n = 16) compared to the other sample
group numbers (n = 8) in the discovery cohort may explain
why we observed statistically significant alterations in
miR-150 and miR-923 in the initial analysis (Table 2) but
not in the validation cohort (Table 3). Despite the variabil-
ity within sample groups, we found circulating levels of
miR-34a and miR-150 to be capable of distinguishing can-
cer patients from the non-malignant group of patients
(Figure 2), in addition they were also capable of delineat-
ing patient groups with different diseases of the colon
from each other (Table 3). Moreover, the discovery
miRNA profiling results (Table 2) provide additional
miRNA candidates, for instance miR-144-5p that may
have potential as circulating miRNA biomarkers of CRC
which can be exploited and independently validated by
(See figure on previous page.)
Figure 1 MiR-34a, miR-150, and miR-923 in the validation cohort. Beeswarm plots of plasma levels of (A) miR-34, (B) miR-150, and (C) miR-923 in
the five sample groups; normal (n = 20), polyp (n = 20), adenoma (n = 20), early stage cancer (stage I/II) (n = 23), and advanced cancer (stage III/IV)
(n = 14). Expression levels of the miRNAs (log10 scale at y-axis) are normalised to let-7e. Statistically significant differences between groups were
determined using Wilcoxon rank sum tests and are represented as follows; p-value <0.05 = *, p-value <0.01 = **, p-value < 0.001 = ***.
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Figure 2 Expression levels of miR-34a, miR-150, and miR-923 in cancerous and non-malignant sample groups in the validation cohort and independent
data set. (A) Cancer samples show significantly higher miR-34a expression (p-value < 0.001) compared to non-malignant samples in both the validation
plasma samples and independent tumour tissue samples. (B) Cancer samples show significantly lower miR-150 expression compared to non-malignant
samples in both the validation plasma samples (p-value =0.003) and independent tumour tissue samples (p-value < 0.001). (C) No significant change in
miR-923 expression is observed in either the validation plasma samples (p-value = 0.56) or the independent tumour tissue samples (p-value = 0.35). The
non-malignant group in the validation cohort represents the normal, polyp, and adenoma samples. Cancer groups in both studies represent cancers of all
stages I-IV. Expression levels of the miRNAs (log10 scale at y-axis) are normalised to let-7e in the validation cohort and mean normalised in the independent
dataset. Statistically significant differences between groups were determined using Wilcoxon rank sum tests in both the validation and independent cohorts.
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other research groups. In our opinion this is an important
step towards the identification of specific biomarkers for
early stages of disease.
There have been several publications examining the
potential for miRNAs to act as circulating biomarkers
for the detection of CRC. Recently, Faltejskova and col-
leagues attempted to validate the serum levels of four
miRNAs (miR-17-3p, miR-29a, miR-92a and miR-135b)
that had been proposed by other groups as potential cir-
culating biomarkers of CRC. They used qPCR to assess
the miRNA expression levels in 100 CRC patients and
30 healthy controls, and did not detect any significant
changes in the expression of any of the miRNAs evalu-
ated [17]. We examined the lists of significantly differen-
tially expressed miRNAs in our discovery cohort to
determine whether we also identified biomarkers found
Figure 3 ROC curve analysis combining plasma levels of the three miRNAs to distinguish advanced cancer from benign disease groups. (A) Plasma
levels of miR-34a, miR-150, and miR-923 discriminate polyp samples (n = 20) from advanced cancer (stage III/IV) samples (n = 14) individually; AUC = 0.796,
0.825, and 0.746 respectively. Combining markers miR-34a and miR-150 increases the AUC to 0.904. miR-923 expression does not improve the fit of the
model and thus is not included in the combination. (B) Plasma levels of miR-150 and miR-923 discriminate adenoma samples (n = 20) from advanced
cancer (stage III/IV) samples (n = 14) individually; AUC = 0.875 and 0.732 respectively. Combining these markers does not improve the fit of the model,
thus miR-150 alone distinguishes adenoma samples from advanced cancer samples with an AUC of 0.875.
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by other groups. We did not find miR-21 [19], miR-141
[38], miR-29a, miR-17-3p or miR-92 [14,16], miR-601 or
miR-760 [15] to be significantly differentially expressed
in any of the disease groups compared to our healthy
controls. We did, however find miR-19a, miR-19b, and
miR-15b significantly altered in some of our compari-
sons (see Table 2). These miRNAs were among those
found by Giráldez et al. to be significantly up-regulated in
plasma samples of CRC patients in their study in 2012 [18].
Although there is some concordance among the re-
sults of different groups in the search for biomarker
miRNAs, uncertainty remains as to which miRNAs are
the most appropriate markers of disease. Disparities in
patient age and time of sample collection (i.e. before or
after surgery/treatment) in different studies may impact
on the reproducibility of results. In addition to these var-
iables, it has been noted previously that miRNA profiles
vary between different ethnic groups [39], male and fe-
male patients [40], and that blood cell contaminants can
contribute to circulating miRNA profiles [40,41]. Blood
cell contaminants of plasma and serum samples may be
of particular importance in evaluating the potential of
circulating miRNAs as biomarkers of disease. In fact,
Pritchard and colleagues suggest that the elevated miR-92a
levels detected in the plasma of patients with colon cancer
are due the higher levels of red blood cell haemolysis in pa-
tients with this disease [41]. This poses the question as to
whether all of these putative biomarkers should be dis-
carded due to their expression in blood cells, or whether
extensive validation and perhaps additional profiling on
larger more diverse patient cohorts will confirm the most
reliable biomarker candidates. We would argue against
discarding biomarkers because of their detection in
hematopoietic cells, particularly if, as we have shown, their
expression reflects that found within the tumour (Figure 2).
If we were to discard markers for their presence in blood
cells, we would also have to discount miR-21 as a valid
marker of disease as it was also detected by Duttagupta and
colleagues [40]. This miRNA is commonly up-regulated in
cancer, has been identified in the serum and stool samples
of cancer patients, and multiple studies have linked its ex-
pression to advanced disease and worse outcome for pa-
tients [42]. In an effort to control confounding factors in
this study, all samples were age and sex matched, blood
was taken at the time of colonoscopy before treatment
commenced, and an additional centrifugation step to re-
move cellular debris prior to RNA extraction recom-
mended by Duttagupta and colleagues [40] was included in
the sample processing.
In order to examine the diagnostic potential of our
three candidate miRNAs in detecting different diseases
of the colon we employed ROC curve analysis. To iden-
tify the most powerful candidate combinations we fo-
cused our analysis on comparing sample groups that
showed significant differential expression of more than
one of the three miRNAs. This approach allowed us to
identify marker combinations which distinguish patient
groups with benign disease of the colon from those with
advanced stage cancer (Figure 3). Specifically, miR-34a
and miR-150 abundance were capable of differentiating
patients with polyps from those with advanced cancer,
AUC= 0.904, and miR-150 abundance separates patients
with adenomas from those with advanced cancer, AUC =
0.875. To further confirm the true diagnostic potential of
these circulating cell-free miRNAs it is now important for
these results to be independently replicated in additional
samples by another group. If this independent validation
were successful, a prospective validation of the miRNA can-
didate biomarkers would be warranted.
Conclusions
To our knowledge this is the first study to examine cir-
culating miRNA levels in samples from patients with
polyps in addition to normal, adenoma, and early stage
and advanced cancer samples. We identified two circu-
lating miRNAs capable of distinguishing patient groups
with different diseases of the colon from each other, and
sets of miRNAs that distinguish patients with advanced
cancer from benign disease groups. We also found miR-34a
expression to be significantly increased in early stage cancer
samples compared to the non-malignant patient samples,
and in adenoma samples compared to normal and polyp
samples.
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